Enhanced interaction with CD8+ T cells and elevated expression of antigen-presentation genes prompted us to investigate how DLBCL-FRCs modulated CD8+ T cell cytotoxicity. The gene discussed is CD8A; the disease is diffuse large B-cell lymphoma.